Delving Into Participation Trends in Renal Cell Carcinoma Studies

The study seeks to delve into the firsthand experiences of patients diagnosed with renal cell carcinoma who partake in a separate clinical study featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.

By joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future renal cell carcinoma patients and play an active role in advancing clinical research.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Renal Cell Carcinoma Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Power Life Sciences

San Francisco, California, 94107, United States

Location contact

Michael B Gill

CONTACT

https://www.withpower.com/[email protected]

415-900-4227

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient has been diagnosed with renal cell carcinoma
Patient is a minimum of 18 years or older
Patient has self-identified as planning to enroll in a clinical study

Exclusion criteria

Patient does not understand, sign, and return consent form
Inability to perform regular electronic reporting
Patient is pregnant

Treatment and study plan

Primary outcomes

Number of patients who decide to participate in a renal cell carcinoma clinical study

Time frame: 3 months
Rate of patients who remain in renal cell carcinoma clinical trial to trial completion

Time frame: 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Michael B Gill

CONTACT

[email protected]

4159004227

Sponsors and collaborators

Lead sponsor

Power Life Sciences Inc.

Industry

Registry information

Official study title

Exploring Engagement Dynamics Among Individuals Impacted by Renal Cell Carcinoma

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2026
First posted: Oct 23, 2023
Registry last updated: Oct 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting